보고서 요약(국문)

개요
전 세계 혈구탐식성 림프조직구증(HLH) 치료 시장은 2022년 YY억 달러에 달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY억 달러에 이를 것으로 예상됩니다.
전 세계 혈구탐식성 림프조직구증(HLH) 치료 시장은 여러 요인의 영향으로 지난 수년간 상당한 성장과 변화를 경험해 왔습니다. 혈구탐식성 림프조직구증(HLH)은 드문 질환으로 주로 영유아에게 발생하며, 일반적으로 소아에게 유전됩니다. 성인의 경우 암이나 감염 등 다양한 질환으로 인해 HLH가 발생할 수 있습니다.
특히 개발도상국을 중심으로 한 정부 투자와 연구는 첨단 제품 및 기술 활용을 촉진하고 전 세계 혈구탐식성 림프조직구증 치료 시장 성장을 견인할 것입니다. 이러한 혁신적인 제품에는 단일클론 항체와 같은 신약의 개발 및 치료 효과 증대가 포함됩니다.

시장 동향: 성장 동력 및 제약 요인
주요 기업 간 인수 및 파트너십 증가
선진국들은 높은 소득 수준, 투자 및 인프라 개발에 힘입어 의료 부문이 빠르게 발전하고 있습니다. 여러 국가에서 혈구탐식성 림프조직구증(HLH) 치료제에 대한 수요가 연구 결과의 긍정적인 결과로 인해 크게 증가하고 있습니다. 주요 기업 간 다양한 인수 및 신제품 출시가 시장 성장을 견인하는 중요한 요인이 될 것입니다.
2023년 3월 9일, 면역요법 분야에서 이중특이항체를 개발한 임상 단계의 바이오제약 회사인 F-star Therapeutics, Inc.가 영국에 본사를 둔 Sino Biopharmaceutical Limited("Sino Biopharm")의 완전 자회사인 invoX Pharma Limited에 총 약 1억 6,100만 달러(주당 7.12달러)의 현금으로 인수되었습니다.

2022년 캐나다 보건 기술 저널(Canadian Journal of Health Technologies)에 따르면, 한 후향적 코호트 연구(종합 검토에 포함됨) 데이터에 따라 아나킨라(Anakinra)는 혈구탐식성 림프조직구증(HLH) 환자의 28일 사망률과 사망 확률을 낮출 수 있습니다.
또한, 혈구탐식성 림프조직구증 관리를 위한 새로운 기술이나 약물의 활용이 증가하고 있습니다. 사람들의 인식이 높아지고 혁신적인 제품 개발을 위한 연구가 활발해짐에 따라 혈구탐식성 림프조직구증 치료 시장 성장을 견인하는 주요 요인이 될 것입니다.
약물 관련 부작용으로는 고혈압, 감염, 주입 관련 이상 반응(발열, 발적, 발진, 발한), 저칼륨혈증, 변비 등이 있습니다. 발열, 쇠약, 기침, 호흡 곤란, 설사, 복부 불편감, 오한, 발한, 배뇨 시 작열감, 빈뇨는 심각한 감염의 증상입니다. 이러한 증상들은 주요 임상 시험에서 흔히 보고된 이상 반응 중 일부입니다. 가미판트 사용자 중 10% 미만에서 발생한 추가적인 등급별 이상반응(모든 등급)에는 구토, 급성 신손상, 무력증, 호흡곤란, 서맥, 위장관 출혈, 코피, 말초 부종이 포함됩니다.
이 보고서에 대한 자세한 내용은 샘플을 요청하십시오.
세그먼트 분석
전 세계 혈구탐식성 림프조직구증(HLH) 치료 시장은 유형, 약물, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
생물학적 제제 부문은 시장 점유율의 약 38%를 차지했습니다.
단클론 항체, 면역 조절제, 성장 인자, 백신, 그리고 사람 혈액 및 혈장으로 만든 제품은 모두 생물학적 의약품이라는 광범위한 범주에 속합니다. 생물학적 치료는 HLH를 악화시키거나 유발할 가능성이 있습니다. 가미판트(에마팔루맙)는 인터페론 감마(IFN) 차단 단클론 항체입니다. 이는 인터페론 감마라는 면역 체계 분자를 억제하여 염증을 감소시킵니다. 그 결과, 원발성 HLH의 염증 관련 증상이 완화됩니다.
2023년 3월 7일, IL-18에 의해 유발되는 심각한 전신 자가염증 질환 및 장애 치료를 위한 신약 개발에 전념하는 생명공학 기업인 AB2 Bio Ltd.가 진행 중인 타데키니그 알파(Tadekinig alfa)의 핵심 3상 임상 연구 등록이 완료되었습니다. 이 임상 시험의 목표는 원발성 단일 유전자 IL-18 유발 HLH 관리에 있어 타데키니그 알파(r-hIL-18BP)의 안전성과 효능을 입증하는 것입니다. HLH는 매우 드물고 치명적인 질환으로, 주로 어린이에게 발생하며 현재까지 승인된 치료법이 없습니다. AB2 Bio에 따르면, 주요 결과는 2023년 하반기에 발표될 예정입니다.
지역별 시장 점유율
북미는 2022년 시장 점유율의 약 36%를 차지했습니다.
의료 분야에서 혈구탐식성 림프조직구증(HLH) 치료에 대한 수요가 증가함에 따라 북미 지역 제조업체들은 사업 확장의 기회를 갖고 있습니다. 북미에는 많은 생산자와 공급업체가 있으며, 이 지역의 빠른 경제 성장으로 산업 생산이 확대되어 혈구탐식성 림프조직구증(HLH) 치료제에 대한 수요가 증가하고 있습니다.
의료비 지출 증가, 연구 개발 확대, 기술 발전 및 다양한 치료 기기 개발, 그리고 이 지역 전반에 걸친 제약 및 의료기기 사업 설립 증가는 혈구탐식성 림프조직구증 치료제 시장 점유율 성장에 기여하고 있습니다. 에마팔루맙과 같은 다양한 혁신적인 신약에 대한 인식이 높아짐에 따라 이 지역의 시장은 성장하고 있습니다. 이러한 요소들은 북미가 세계 시장에서 주도적인 위치를 차지하고 있음을 더욱 뒷받침합니다.
북미는 미국을 중심으로 전 세계 혈구탐식성 림프조직구증 치료제 시장에서 핵심적인 역할을 계속하고 있습니다. 정부의 인프라 개발 및 투자 촉진 정책과 첨단 기술 발전에 대한 관심은 미국 내 혈구탐식성 림프조직구증(HLM) 치료 수요를 촉진했습니다. 미국은 HLM 치료 수요를 자극하는 여러 정책을 적극적으로 추진해 왔습니다.
COVID-19 영향 분석
2019년 말 발생한 COVID-19 팬데믹은 전 세계 산업, 특히 HLM 치료 시장에 전례 없는 어려움을 초래했습니다. 각국이 봉쇄, 공급망 차질, 경제 활동 위축에 직면하면서 다양한 의료기기의 주요 소비자인 제약 부문은 큰 타격을 입었습니다. 2020년 초부터 시작된 팬데믹의 광범위한 봉쇄와 제한 조치는 전 세계적으로 여러 사업에 영향을 미쳤습니다.
주요 의료기기 산업은 생산이 중단되고 COVID-19 관리에 집중하면서 HLM 치료 수요가 급감했습니다. 현재 여러 연구가 시작되었고, 기업들은 제품의 안전성과 효능에 대한 임상 시험을 다시 시작했습니다. 전반적으로, 전 세계 혈구탐식성 림프조직구증 치료 시장에 대한 팬데믹의 영향은 비교적 미미할 것으로 예상되며, 타데키니그 알파와 같은 새로운 치료법 및 기타 혈구탐식성 림프조직구증 관리 프로그램에 대한 지속적인 수요와 연구로 인해 시장은 꾸준히 성장할 것으로 전망됩니다.
주요 개발 사항
• 2023년 1월 30일, 시노바이오팜과 계열사 CTTQ는 광저우 개발구 관리위원회와 지역 남부 거점 및 국제 혁신 허브 설립에 투자하기 위한 기본 협약을 체결했습니다. 연구 개발, 제조, 판매 및 마케팅 서비스를 점진적으로 통합함으로써 광저우 발명 센터는 시노 바이오팜의 "제2의 엔진"으로 성장하여 2030년까지 매출 1,000억 홍콩달러 달성이라는 회사 목표 달성에 기여할 것입니다.
• 2022년 12월 10일, 미국 혈액학회에 따르면 2상 임상 연구에 참여한 환자들은 8주 동안 덱사메타손과 룩솔리티닙(15mg 1일 2회)을 투여받았습니다. 경구 투여되는 야누스 키나제(JAK) 억제제인 룩솔리티닙은 혈구탐식성 림프구증(HLH)에서 활성화되는 JAK 효소와 하류 사이토카인을 억제하지만, 일부 JAK 경로 활성화 사이토카인은 코르티코스테로이드 내성을 유발할 수 있습니다. 시험관 내 및 생체 내 실험에 따르면 룩솔리티닙은 이러한 현상을 역전시키는 데 도움이 될 수 있습니다. 연구진에 따르면 이 약물은 내약성이 우수했으며, 용량 조절이 필요한 환자는 없었습니다.

경쟁 환경
시장의 주요 글로벌 업체로는 Swedish Orphan Biovitrum, Incyte, Sanofi, AB2 Bio Ltd., Genentech, Inc., Pfizer Inc., Viatris Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited 및 Merck KGaA가 있습니다.
보고서 구매 이유

• 유형, 약물, 투여 경로, 유통 채널 및 지역별 글로벌 혈구탐식성 림프조직구증 치료 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 식별합니다.

• 모든 세그먼트를 포함한 혈구탐식성 림프조직구증 치료 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 모든 주요 업체의 핵심 제품을 포함하는 제품 맵핑 Excel 파일을 제공합니다.

글로벌 혈구탐식성 림프조직구증 치료 시장 보고서는 약 69개의 표, 67개의 그림, 그리고 186페이지 분량으로 구성될 예정입니다.
대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global hemophagocytic lymphohistiocytosis treatment market reached US$ YY billion in 2022 and is expected to reach US$ YY billion by 2030, growing with a CAGR of YY% during the forecast period 2023-2030.
The global hemophagocytic lymphohistiocytosis treatment market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. Hemophagocytic lymphohistiocytosis (HLH), an uncommon illness, primarily affects babies and young children. The condition typically passes down to children. Adults can develop HLH from a wide range of illnesses, such as cancer and infections.
Government investments and research, particularly in developing economies, will continue to drive utilization of advanced products or technologies and boost the global hemophagocytic lymphohistiocytosis treatment market. The respective innovative products includes the use of novel drugs such as monoclonal antibodies for better treatment.
Market Dynamics: Drivers & Restraints
Growing acquisition and partnerships among key players
Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high income levels, investments and infrastructure development. Several countries have experienced substantial demand for Hemophagocytic Lymphohistiocytosis Treatment owing to its positive outcomes in research. Various acquisitions and product launches among key players will be a crucial factor driving the growth of the market.
On March 9, 2023, F-star Therapeutics, Inc., a biopharmaceutical company in the clinical stage that invented bispecific antibodies in immunotherapy, has been successfully acquired by invoX Pharma Limited, a fully-owned subsidiary based in U.K. of Sino Biopharmaceutical Limited ("Sino Biopharm"), for a total approximate cash valuation of $161 million (or $7.12 per share).
According to Canadian Journal of Health Technologies 2022, Anakinra may lower 28-day mortality and the probability of death in people with hemophagocytic lymphohistiocytosis (HLH), according to data from one retrospective cohort research (included in one comprehensive review).
Furthermore, the rising utilization of novel technologies or drugs for the management of hemophagocytic lymphohistIocytosis. Rising awareness among people and increasing research for innovative product development will be a major factor driving the growth of the hemophagocytic lymphohistiocytosis treatments market.
Side effects associated with the medication
High blood pressure, infections, infusion-related adverse responses (fever, redness, rash, sweating), low blood potassium, fever, and constipation are typical side effects. Fever, weakness, coughing, trouble breathing, diarrhea, stomach discomfort, chills, sweating, burning sensations while urinating, and more frequent urination are symptoms of a serious infection. These were the few commonly reported adverse events in the key trial. Gamifant users who experienced less than 10% of these additional graded adverse effects (all grades) included vomiting, acute renal injury, asthenia, dyspnea, bradycardia, gastrointestinal bleeding, epistaxis, and peripheral edema.
For more details on this report - Request for Sample
Segment Analysis
The global hemophagocytic lymphohistiocytosis treatment market is segmented based on type, medication, route of administration, distribution channel and region.
Biologics segment accounted for approximately 38% of market share
Monoclonal antibodies, immune modulators, growth factors, vaccinations, and items made from human blood and plasma all fall within the broad category of biological medicines. Biological treatments have the potential to worsen or possibly start HLH. An interferon gamma (IFN) blocking monoclonal antibody is what Gamifant (emapalumab) is. It reduces inflammation by inhibiting an immune system molecule called interferon gamma. The inflammation-related symptoms of primary HLH are lessened as a result.
On March 7, 2023, the enrollment in the ongoing pivotal Phase 3 research of Tadekinig alfa by AB2 Bio Ltd., a biotechnology business dedicated to discovering novel medicines for the treatment of serious systemic autoinflammatory illnesses and disorders induced by IL-18, has been completed. The goal of the trial is to demonstrate the safety and efficacy of Tadekinig alfa (r-hIL-18BP) for the management of primary monogenic IL-18 led HLH, an extremely rare and fatal illness that primarily affects children and lacks any approved treatments. Topline findings are expected in the second half of 2023, according to AB2 Bio.
Geographical Penetration
North America accounted for around 36% of market share in 2022
Due to the rising need for hemophagocytic lymphohistiocytosis treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for hemophagocytic lymphohistiocytosis treatment.
Increasing expenditure on healthcare and rising research studies, advancement of technologies and different type of devices for management, and increase in pharmaceutical or medical device business establishment across the region are also contributing to the growth of hemophagocytic lymphohistiocytosis treatment market share of this region. The market in this area is growing as people become more aware of various novel innovative drugs such as emapalumab. The aforementioned elements further attest to North America's hegemonic position in the world.
North America continues to be a key player in the global hemophagocytic lymphohistiocytosis treatment market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for hemophagocytic lymphohistiocytosis treatment in the U.S. United States have been proactive in executing several initiatives or researches, stimulating hemophagocytic lymphohistiocytosis treatment demand.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global hemophagocytic lymphohistiocytosis treatment market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various device designs, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.
Major medical device industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for hemophagocytic lymphohistiocytosis treatment. Now several research studies have been initiated and companies have again started trial for their products safety and efficacy. Overall, the impact of the pandemic on the global hemophagocytic lymphohistiocytosis treatment market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for novel therapies, like tadekinig alfa and other programs for management of hemophagocytic lymphohistiocytosis.
Key Developments
• On January 30, 2023, with the Guangzhou Development Zone Administrative Committee, Sino Biopharm plus its affiliate CTTQ signed a framework agreement to invest in the creation of a regional Southern base and an international innovation hub in the area. By gradually integrating R&D, manufacturing, sales, and marketing services, the Guangzhou invention center will grow to be Sino Biopharm's "second engine" and help the company reach its revenue goal of HK$100 billion by 2030.
• On December 10, 2022, According to American Society of Hematology, patients in the phase II study got dexamethasone and ruxolitinib (15 mg twice daily) over an eight-week period. Janus kinase (JAK) inhibitor which is orally administered is called roxolitinib inhibits JAK enzymes along with downstream cytokines that are active in HLH, however some JAK-pathway-activated cytokines can lead to glucocorticoid resistance. Ruxolitinib may be able to help reverse this, according to in vitro and in vivo experiments. The medication was well tolerated, according to researchers, and no patients needed dose adjustments.
Competitive Landscape
The major global players in the market include Swedish Orphan Biovitrum, Incyte, Sanofi, AB2 Bio Ltd., Genentech, Inc., Pfizer Inc., Viatris Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited and Merck KGaA.
Why Purchase the Report?
• To visualize the global hemophagocytic lymphohistiocytosis treatment market segmentation based on type, medication, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of hemophagocytic lymphohistiocytosis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global hemophagocytic lymphohistiocytosis treatment market report would provide approximately 69 tables, 67 figures and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Medication
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing acquisition and partnerships among key players
4.1.1.2. Rising technological advancements and developments
4.1.2. Restraints
4.1.2.1. Side effects associated with the medication
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. SWOT Analysis
5.6. Patent Analysis
5.7. Russia-Ukraine War Impact Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Familial Hemophagocytic Lymphohistiocystosis*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Acquired Hemophagocytic Lymphohistiocystosis
8. By Medication
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
8.1.2. Market Attractiveness Index, By Medication
8.2. Antineoplastic Agents*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Etoposide (Toposar, VePesid)
8.2.4. Methotrexate (Trexall)
8.2.5. Cisplatin
8.3. Corticosteroids
8.3.1. Dexamethasone (Decadron, Hexadrol)
8.3.2. Methylprednisolone
8.4. Immunosuppressant Agents
8.4.1. Cyclosporine (Sandimmune, Neoral)
8.4.2. Rituximab (Rituxan)
8.5. Biologics
8.5.1. Emapalumab (Gamifant, emapalumab-lzsg)
8.5.2. Alemtuzumab (Campath)
8.5.3. Tadekinig Alfa
8.6. Immune Globulins
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Parenteral
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Swedish Orphan Biovitrum*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Incyte
13.3. Sanofi
13.4. AB2 Bio Ltd.
13.5. Genentech, Inc.
13.6. Pfizer Inc.
13.7. Viatris Inc.
13.8. Bristol-Myers Squibb Company
13.9. Takeda Pharmaceutical Company Limited
13.10. Merck KGaA
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Swedish Orphan Biovitrum, 4. Key Developments, Incyte, Sanofi, AB2 Bio Ltd., Genentech, Inc., Pfizer Inc., Viatris Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Merck KGaA

표 목록 (Tables)

List of Tables Table 1 Global Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Medication, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Type, 2022, 2026 & 2030 (US$ Million)

Table 7 Global Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 8 Global Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Medication, 2022, 2026 & 2030 (US$ Million)

Table 9 Global Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Medication, 2021-2030 (US$ Million)

Table 10 Global Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 11 Global Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 12 Global Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 13 Global Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 14 Global Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 15 Global Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Region, 2021-2030 (US$ Million)

Table 16 North America Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 17 Global Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Medication, 2022, 2026 & 2030 (US$ Million)

Table 18 North America Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 19 North America Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 20 North America Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 21 South America Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 22 South America Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Medication, 2021-2030 (US$ Million)

Table 23 South America Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 24 South America Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 25 South America Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 26 Europe Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 27 Europe Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Medication, 2021-2030 (US$ Million)

Table 28 Europe Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 29 Europe Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 30 Europe Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 31 Asia-Pacific Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 32 Asia-Pacific Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Medication, 2021-2030 (US$ Million)

Table 33 Asia-Pacific Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 34 Asia-Pacific Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 35 Asia-Pacific Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 36 Middle East & Africa Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 37 Middle East & Africa Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Medication, 2021-2030 (US$ Million)

Table 38 Middle East & Africa Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 39 Middle East & Africa Hemophagocytic Lymphohistiocytosis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 40 Swedish Orphan Biovitrum: Overview

Table 41 Swedish Orphan Biovitrum: Product Portfolio

Table 42 Swedish Orphan Biovitrum: Key Developments

Table 43 Incyte: Overview

Table 44 Incyte: Product Portfolio

Table 45 Incyte: Key Developments

Table 46 Sanofi: Overview

Table 47 Sanofi: Product Portfolio

Table 48 Sanofi: Key Developments

Table 49 AB2 Bio Ltd.: Overview

Table 50 AB2 Bio Ltd.: Product Portfolio

Table 51 AB2 Bio Ltd.: Key Developments

Table 52 Genentech, Inc.: Overview

Table 53 Genentech, Inc.: Product Portfolio

Table 54 Genentech, Inc.: Key Developments

Table 55 Pfizer Inc.: Overview

Table 56 Pfizer Inc.: Product Portfolio

Table 57 Pfizer Inc.: Key Developments

Table 58 Viatris Inc.: Overview

Table 59 Viatris Inc.: Product Portfolio

Table 60 Viatris Inc.: Key Developments

Table 61 Bristol-Myers Squibb Company: Overview

Table 62 Bristol-Myers Squibb Company: Product Portfolio

Table 63 Bristol-Myers Squibb Company: Key Developments

Table 64 Takeda Pharmaceutical Company Limited: Overview

Table 65 Takeda Pharmaceutical Company Limited: Product Portfolio

Table 66 Takeda Pharmaceutical Company Limited: Key Developments

Table 67 Merck KGaA: Overview

Table 68 Merck KGaA: Product Portfolio

Table 69 Merck KGaA: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Hemophagocytic Lymphohistiocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 2 Global Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 3 Global Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Medication, 2022 & 2030 (%)

Figure 4 Global Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 5 Global Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 6 Global Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Hemophagocytic Lymphohistiocytosis Treatment Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 8 Familial Hemophagocytic Lymphohistiocystosis Hemophagocytic Lymphohistiocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 9 Acquired Hemophagocytic Lymphohistiocystosis Hemophagocytic Lymphohistiocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 10 Global Hemophagocytic Lymphohistiocytosis Treatment Market Y-o-Y Growth, By Medication, 2022-2030 (%)

Figure 11 Antineoplastic Agents Medication in Global Hemophagocytic Lymphohistiocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 12 Corticosteroids Medication in Global Hemophagocytic Lymphohistiocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 13 Immunosuppressant Agents Medication in Global Hemophagocytic Lymphohistiocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 14 Biologics Medication in Global Hemophagocytic Lymphohistiocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 15 Immune Globulins Medication in Global Hemophagocytic Lymphohistiocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 16 Global Hemophagocytic Lymphohistiocytosis Treatment Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 17 Oral Route of Administration in Global Hemophagocytic Lymphohistiocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 18 Parenteral in Global Hemophagocytic Lymphohistiocytosis Treatment Market Value, 2021-2030 (US$ Million

Figure 19 Global Hemophagocytic Lymphohistiocytosis Treatment Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 20 Hospital Pharmacies Distribution Channel in Global Hemophagocytic Lymphohistiocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 21 Retail Pharmacies Distribution Channel in Global Hemophagocytic Lymphohistiocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 22 Online Pharmacies Distribution Channel in Global Hemophagocytic Lymphohistiocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 23 Global Hemophagocytic Lymphohistiocytosis Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 24 North America Hemophagocytic Lymphohistiocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 25 Asia-Pacific Hemophagocytic Lymphohistiocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 26 Europe Hemophagocytic Lymphohistiocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 27 South America Hemophagocytic Lymphohistiocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 28 Middle East and Africa Hemophagocytic Lymphohistiocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 29 North America Hemophagocytic Lymphohistiocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 30 North America Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 31 North America Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 32 North America Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Medication, 2022 & 2030 (%)

Figure 33 North America Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 34 North America Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 35 South America Hemophagocytic Lymphohistiocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 36 South America Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 37 South America Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 38 South America Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Medication, 2022 & 2030 (%)

Figure 39 South America Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 40 South America Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 41 Europe Hemophagocytic Lymphohistiocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 42 Europe Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 43 Europe Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 44 Europe Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Medication, 2022 & 2030 (%)

Figure 45 Europe Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 46 Europe Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 47 Asia-Pacific Hemophagocytic Lymphohistiocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 48 Asia-Pacific Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 49 Asia-Pacific Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 50 Asia-Pacific Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Medication, 2022 & 2030 (%)

Figure 51 Asia-Pacific Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 52 Asia-Pacific Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 53 Middle East & Africa Hemophagocytic Lymphohistiocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 54 Middle East & Africa Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 55 Middle East & Africa Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 56 Middle East & Africa Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Medication, 2022 & 2030 (%)

Figure 57 Middle East & Africa Hemophagocytic Lymphohistiocytosis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 58 Swedish Orphan Biovitrum: Financials

Figure 59 Incyte: Financials

Figure 60 Sanofi: Financials

Figure 61 AB2 Bio Ltd.: Financials

Figure 62 Genentech, Inc.: Financials

Figure 63 Pfizer Inc.: Financials

Figure 64 Viatris Inc.: Financials

Figure 65 Bristol-Myers Squibb Company: Financials

Figure 66 Takeda Pharmaceutical Company Limited: Financials

Figure 67 Merck KGaA: Financials

세계 혈구탐식성 림프조직구증 치료 시장 – 2023-2030

Global Hemophagocytic Lymphohistiocytosis Treatment Market -2023-2030